Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | DPP4 | P27487 | 1/20 | 0.49 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.45 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.45 |
| ▸ | DRD1 | P21728 | 2/20 | 0.45 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.45 |
| ▸ | HTR2A | P28223 | 2/20 | 0.45 |
| ▸ | HRH1 | P35367 | 2/20 | 0.45 |
| ▸ | DRD3 | P35462 | 2/20 | 0.45 |
| ▸ | HTR2B | P41595 | 2/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3629712 | 0.95 | L3MBTL3 (0.49) | L3MBTL3L3MBTL1DPP4CACNA1GOPRM1 | |
| SCHEMBL3629618 | 0.94 | L3MBTL3 (0.48) | L3MBTL3L3MBTL1DPP4CACNA1GOPRM1 | |
| SCHEMBL3626074 | 0.94 | L3MBTL3 (0.48) | L3MBTL3L3MBTL1DPP4CACNA1GOPRM1 | |
| SCHEMBL8476569 | 0.91 | DPP4 (0.53) | L3MBTL3L3MBTL1DPP4CACNA1GOPRM1 | |
| SCHEMBL3630899 | 0.90 | L3MBTL3 (0.53) | L3MBTL3L3MBTL1DPP4CACNA1GOPRM1 | |
| SCHEMBL13597015 | 0.84 | DPP4 (0.63) | L3MBTL3L3MBTL1DPP4OPRM1CHRM2 | |
| SCHEMBL3457813 | 0.84 | L3MBTL3 (0.50) | L3MBTL3L3MBTL1DPP4OPRM1CHRM2 | |
| SCHEMBL6778069 | 0.84 | L3MBTL3 (0.50) | L3MBTL3L3MBTL1DPP4OPRM1CHRM2 | |
| SCHEMBL8473371 | 0.83 | L3MBTL3 (0.56) | L3MBTL3L3MBTL1DPP4OPRM1CHRM2 | |
| SCHEMBL3457628 | 0.83 | L3MBTL3 (0.49) | L3MBTL3L3MBTL1DPP4OPRM1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040029861-A1 | Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression | KLINGE PHARMA GMBH | 2004-02-12 | — | — | US | disclosed |
| EP-0912176-B1 | USE OF PYRIDYL ALKANE, PYRIDYL ALKENE AND/OR PYRIDYL ALKINE ACID AMIDES IN THE TREATMENT OF TUMORS OR FOR IMMUNOSUPPRESSION | FUJISAWA DEUTSCHLAND GMBH (DE) | 2002-09-25 | — | — | EP | disclosed |
| US-6451816-B1 | Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression | KLINGE PHARMA GMBH (DE) | 2002-09-17 | — | — | US | disclosed |
| EP-0912176-A1 | USE OF PYRIDYL ALKANE, PYRIDYL ALKENE AND/OR PYRIDYL ALKINE ACID AMIDES IN THE TREATMENT OF TUMORS OR FOR IMMUNOSUPPRESSION | Klinge Pharma GmbH (DE) | 1999-05-06 | — | — | EP | disclosed |
| US-5872115-A | COMPOUNDS FOR TREATMENT OF HYPERCHOLESTEROLEMIA, ISCHEMIC HEART DISEASE, CEREBROVASCULAR DISEASE OR ATHEROSCLEROSIS | GRELAN PHARMACEUTICAL CO. LTD. (JP) | 1999-02-16 | — | — | US | disclosed |
| WO-1997048397-A1 | USE OF PYRIDYL ALKANE, PYRIDYL ALKENE AND/OR PYRIDYL ALKINE ACID AMIDES IN THE TREATMENT OF TUMORS OR FOR IMMUNOSUPPRESSION | KLINGE PHARMA GMBH (DE) | 1997-12-24 | — | — | WO | disclosed |
| EP-0742208-A1 | 2-Ureido-benzamide derivatives | GRELAN PHARMACEUTICAL CO., LTD. (JP) | 1996-11-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029861-A1 | Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression | ALK, IDO1, PDXK | L3MBTL3 3545/4885L3MBTL1 2726/4885DPP4 3001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.